Mission Video

What we do

Bring Health to Light, Empower Longevity

As the earlier a problem is detected, the clearer the path to health.
We’re focused on changing the way we approach cancer, by enabling promising early cancer detection capabilities, in the form of a single draw blood-based screening, to be an integral routine in primary medical care.

Bring Health to Light, Empower Longevity

As the earlier a problem is detected,
the clearer the path to health.
We’re focused on changing the way we
approach cancer, by enabling promising
early cancer detection capabilities, in the
form of a single draw blood-based screening,
to be an integral routine in primary medical care.

Bring Health to Light,Command Longevity

Because the earlier a problem is detected, the clearer the path to health.
That’s why we’re working to provide visibility into an individual’s Realtime state of health, by delivering the most accurate early cancer detection results possible before symptoms occur.

The Gamechanger

MPS-1 Targets Detection over Identification

Our diagnostics utilize a Single Common protein MPS-1, normally present in all humans at low levels in the body’s cells, but present at “abnormally higher” levels in patients with cancers, as a marker to detect and monitor all cancers, at their earliest stages.
Today’s currently available, but limited cancer specific imaging and blood-based screenings are inefficient and come up short, testing only for breast, cervical, colorectal or lung cancers. In addition, research indicates that cancers can be polygenic in origin complicating cancer detection when employing single “cancer specific” gene markers.
By focusing testing solely on this measurable target protein, commonly over-expressed in the blood by cancer growths, MPS-1 diagnostics display promise to work in concert with current recommended tests, supplementing screening where it is lacking, and as a future candidate to enable a more complete preliminary multi-cancer screening, detecting the broadest range of cancers early.
MPS-1 TEST

MPS-1 Efficiencies Drive
Rapid Confident Results

This Single common marker approach, with inherently few comorbidities, exhibits both low false positive or negative rates and the ability to correctly identify people with and without disease, in as little as 24hours.
In multiple studies, including those published in CANCER GENOMICS & PROTEOMICS in 2012 MPS-1 displayed high efficacies, with sensitivities greater than 89%. and specificities greater than 75%. These results show potential of MPS-1 for clear and decisive early cancer detection which can provide the opportunity for earlier treatment, and dependable follow-on monitoring.
READ STUDIES

Building One for All

Leveraging MPS-1 Single marker cost efficiencies, we’re working to provide diagnostics with the capability to enable routine Cancer screening that is affordable and accessible to everyone. In order to meet these goals we are developing funding programs to assist us in laboratory buildout and maintaining the necessary regulatory certifications while in service.

A Partner in the Journey

Beyond detection, the National Cancer Screen is developing clinical partner and patient support resources to help medical practitioners and their patients on their health journey, as well as establish further clinical data and testing to enhance and expand application of MPS-1 diagnostic capabilities.
Support

Building One for All

Leveraging MPS-1 Single marker cost efficiencies, we’re working to provide diagnostics with the capability to enable routine Cancer screening that is affordable and accessible to everyone. In order to meet these goals we are developing funding programs to assist us in laboratory buildout and maintaining the necessary regulatory certifications while in service.

A Partner in the Journey

Beyond detection, the National Cancer Screen is developing clinical partner and patient support resources to help medical practitioners and their patients on their health journey, as well as establish further clinical data and testing to enhance and expand application of MPS-1 diagnostic capabilities.
HELP

MAKE YOUR MARK

*From Venture Partners to Clinical or Research Implementations or Media.  

Get on Board

© 2021 National Cancer Screen, LLC.  All rights reserved. 

  • © 2021 National Cancer Screen, LLC.
    All rights reserved.